Capricor Therapeutics to Report First Quarter 2026 Financial Results and Provide Recent Corporate Update on May 12
Rhea-AI Summary
Capricor Therapeutics (NASDAQ: CAPR) will release first quarter 2026 financial results after market close on May 12, 2026 and will host a conference call and webcast the same day at 4:30 p.m. ET. A replay will be available in the Investors section of capricor.com.
The company described its lead candidate Deramiocel (late-stage development for Duchenne muscular dystrophy) and its StealthX exosome platform in preclinical work.
Positive
- None.
Negative
- None.
News Market Reaction – CAPR
In the May 5 session, CAPR declined 1.61%, reflecting a mild negative market reaction. Argus tracked a peak move of +4.4% during that session. Our momentum scanner triggered 25 alerts that day, indicating elevated trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Apr 22 | Phase 3 data update | Positive | -0.9% | HOPE-3 Phase 3 results showed meaningful functional benefit and BLA under review. |
| Mar 12 | Earnings and update | Positive | -8.7% | Q4/FY 2025 results with positive HOPE-3 data and cash of $318.1M through 2027. |
| Mar 12 | Conference data | Positive | -0.5% | Additional HOPE-3 data at MDA 2026 showing functional and cardiac benefits in DMD. |
| Mar 10 | Regulatory update | Positive | +9.0% | FDA lifted CRL and set new BLA PDUFA date of August 22, 2026 for Deramiocel. |
| Mar 09 | Earnings date notice | Neutral | +9.8% | Announcement of date and time for Q4/FY 2025 results and corporate update call. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent history shows mixed reactions: strong positive regulatory and event updates sometimes led to gains, but several clearly positive clinical and financial milestones saw modest to sharp declines, suggesting a tendency toward profit-taking or skepticism on good news.
Over the past few months, Capricor has highlighted late-stage progress for Deramiocel in Duchenne muscular dystrophy, including positive Phase 3 HOPE-3 data and a BLA under FDA review with a PDUFA date of August 22, 2026. Earnings and corporate updates emphasized cash of about $318.1 million supporting operations through 2027 and a commercialization deal with Nippon Shinyaku. Today’s scheduling of the Q1 2026 earnings call continues a pattern of regular updates around Deramiocel and corporate readiness.
Key Terms
allogeneic medical
cardiac-derived cell therapy medical
Duchenne muscular dystrophy medical
exosome-based therapeutics medical
oligonucleotides medical
forward-looking statements regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
– Company to Host Conference Call on May 12, 2026, at 4:30 p.m. ET –
SAN DIEGO, May 04, 2026 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare diseases, today announced that it will release its financial results for the first quarter ended March 31, 2026, after the market close on Tuesday, May 12, 2026. Management will host a conference call and webcast at 4:30 p.m. ET that same day.
| Title: | Capricor Therapeutics First Quarter 2026 Financial Results and Recent Corporate Update Conference Call and Webcast |
| Date: | Tuesday, May 12, 2026 |
| Time: | 4:30 p.m. ET |
| Call Details: | Toll-Free: 1-800-717-1738 International: 1-646-307-1865 Conference ID: 60968 Participants may dial in using the numbers above and ask to be joined to the call, or use the Call Me™ link for instant telephone access to the event. |
| Webcast: | Click Here |
A replay of the webcast will be available shortly after the conclusion of the live event and will be accessible in the Investors section of the Company’s website at www.capricor.com.
About Capricor Therapeutics
Capricor Therapeutics (NASDAQ: CAPR) is a biotechnology company dedicated to advancing transformative cell and exosome-based therapeutics to redefine the treatment landscape for rare diseases. At the forefront of our innovation is our lead product candidate, Deramiocel, an allogeneic cardiac-derived cell therapy that is currently in late-stage development for the treatment of Duchenne muscular dystrophy (DMD). Extensive preclinical and clinical data have demonstrated Deramiocel’s potent immunomodulatory and anti-fibrotic effects in helping to preserve cardiac and skeletal muscle function in DMD. Capricor is also leveraging the power of its exosome technology, using its proprietary StealthX™ platform in preclinical development focused on vaccinology and the targeted delivery of oligonucleotides, proteins, and small-molecule therapeutics, with the potential to treat and prevent a wide range of diseases. At Capricor, we are committed to pushing the boundaries of possibility and forging a path toward transformative treatments for those in need. For more information, visit capricor.com, and follow Capricor on Facebook, Instagram and X.
Cautionary Note Regarding Forward-Looking Statements
Statements in this press release regarding the efficacy, safety, and intended utilization of Capricor’s product candidates; the initiation, conduct, size, timing and results of clinical trials; the pace of enrollment of clinical trials; plans regarding regulatory filings, future research and clinical trials; regulatory developments involving products, including future interactions with regulatory authorities and the ability to obtain regulatory approvals or otherwise bring products to market; manufacturing capabilities; dates for regulatory meetings; the potential that required regulatory inspections may be delayed or not be successful which would delay or prevent product approval; the ability to achieve product milestones and to receive milestone payments from commercial partners; and any other statements about Capricor’s management team’s future expectations, beliefs, goals, plans or prospects constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words “believes,” “plans,” “could,” “anticipates,” “expects,” “estimates,” “should,” “target,” “will,” “would” and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements. More information about these and other risks that may impact Capricor’s business is set forth in Capricor’s Annual Report on Form 10-K for the year ended December 31, 2025, as filed with the Securities and Exchange Commission on March 17, 2026. All forward-looking statements in this press release are based on information available to Capricor as of the date hereof, and Capricor assumes no obligation to update these forward-looking statements.
Capricor has entered into an agreement for the exclusive commercialization and distribution of Deramiocel for DMD in the United States and Japan with Nippon Shinyaku Co., Ltd. (U.S. subsidiary: NS Pharma, Inc.), subject to applicable regulatory approvals. Deramiocel and the StealthX™ vaccine are investigational candidates and have not been approved for commercial use in any indication.
For more information, please contact:
Capricor Media Contact:
Caitlin Kasunich
KCSA Strategic Communications
ckasunich@kcsa.com
212.896.1241
Capricor Company Contact:
AJ Bergmann, Chief Financial Officer
abergmann@capricor.com
858.727.1755
